Genetic modification of T-cell

"Genetic modification of T-cells" refers to a biotechnological process in which a patient's own immune cells—specifically, their T lymphocytes—are collected and then altered in a laboratory to express new genes that enhance their ability to recognize and attack disease targets such as cancer. This is typically achieved by introducing genes encoding synthetic receptors like chimeric antigen receptors (CARs) or high-affinity tumor-specific T-cell receptors (TCRs) using viral vectors. These modifications enable the resulting "engineered" or "gene-modified" T-cells to better identify and destroy cancerous cells that would otherwise evade natural immune detection. The approach has led to several approved therapies for blood cancers and is being explored for solid tumors as well. However, "genetic modification of T-cells" itself is not a molecular target but rather an advanced therapeutic strategy involving various molecular targets depending on the gene introduced into the cells[1][4][5].

Other names

Genetically engineered T cellEngineered T cellModified T cellGene-modified T cellAdoptive genetically modified T-cell therapy

The mechanism depends on the specific gene introduced; for example, chimeric antigen receptor expression enables direct tumor targeting[1][4][5].